trending Market Intelligence /marketintelligence/en/news-insights/trending/ft1ns3vu7miiv9vrlxy0ea2 content esgSubNav
In This List

Adaptimmune chief technology officer to resign

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise

Blog

Insight Weekly: US companies boost liquidity; auto insurers hike rates; office sector risk rises


Adaptimmune chief technology officer to resign

Adaptimmune Therapeutics plc said Gwen Binder would step down as the company's chief technology officer at the end of January 2019.

Binder was the first U.S. employee of Adaptimmune in 2011, coming from the company's T-cell translational development collaboration program with the University of Pennsylvania.

Abingdon, U.K.-based Adaptimmune operates as a clinical-stage biopharmaceutical company that offers novel cancer immunotherapy products.